Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avoralstat (BCX4161) Prophylaxis in HAE (OPuS-1)
NCT01984788Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Nov 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of avoralstat in hereditary angioedema (HAE) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Number of acute angioedema attacks at 28 days. Started Nov 2013; status: completed.
02
Drugs
avoralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT01984788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01984788.